세계의 비호르몬성 피임약 시장 : 기회, 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Non-Hormonal Contraceptives Market was valued at USD 19.9 billion in 2024 and is estimated to grow at a CAGR of 7% to reach USD 39.1 billion by 2034. Rising public awareness around safe sexual practices, combined with supportive government initiatives and a noticeable shift toward hormone-free contraceptive solutions, continues to drive market expansion. A growing number of consumers are seeking birth control options that avoid the side effects commonly linked with hormonal methods.

An increasing preference for accessible and easy-to-use contraceptives like condoms has positively impacted market dynamics. The market had a strong uptake among men in developing regions due to affordability, availability, and dual protection against pregnancy and STDs. Many users are moving away from hormone-based options due to side effects such as mood fluctuations and weight gain, contributing to the growing demand for safer alternatives. Additionally, wide product availability through multiple retail and digital channels enhances consumer access. Products are conveniently offered via online platforms, drugstore chains, and nearby retail outlets, encouraging consistent adoption. These factors are collectively expected to sustain growth in the coming years.

The devices segment is projected to achieve a CAGR of 7.2%, reaching USD 29.4 billion by 2034. Key products in this segment include intrauterine devices (IUDs), subdermal implants, vaginal rings, and condoms. Among these, copper IUDs have become widely preferred due to their effectiveness and hormone-free nature. Condoms remain an essential method due to their accessibility and added protection against infections, making them a dominant player in the non-hormonal contraceptives space.

In 2024, the female user segment accounted for USD 12.6 billion. Women continue to opt for non-hormonal solutions including long-acting reversible contraceptives (LARCs), spermicidal products, implants, and surgical procedures like tubectomy. Choices are often influenced by convenience, health factors, and long-term reliability. Tubal ligation, a permanent sterilization procedure involving the closure of fallopian tubes, is commonly selected by women over 40 who seek a dependable birth control method as they approach menopause. Rising disposable income, increased participation of women in the workforce, and greater reproductive health awareness are also contributing to higher adoption.

U.S. Non-Hormonal Contraceptives Market was valued at USD 5.8 billion in 2024. Individuals managing hormonal conditions such as polycystic ovary syndrome or thyroid disorders often rely on non-hormonal options. Market growth is further supported by varying cultural and legal restrictions on abortion, prompting greater use of contraception. Technological advances in sterilization, including minimally invasive options for both men and women, are improving patient experience and acceptance. Additionally, industry players are focusing on developing next-generation solutions for male contraception, including injectable hydrogel-based methods, which is expected to boost future demand.

Key companies in the Global Non-Hormonal Contraceptives Market include: Bayer, Reckitt, MAYER, HLL Lifecare, PREGNA INTERNATIONAL, FUJI LATEX, Mankind, CooperCompanies, Church & Dwight Co., SMB, CUPID, Okamoto, abbVie, and VIATRIS. To strengthen their foothold in the non-hormonal contraceptives sector, leading companies prioritize innovation in product design, expand distribution channels, and launch targeted awareness campaigns. Many are developing advanced barrier devices and sterilization tools that offer greater comfort, efficiency, and accessibility. Companies invest in user-centric education to break cultural taboos and promote informed choices.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising concerns over side effects of hormonal contraceptives
    • 3.2.1.2 Growing inclination towards planned delayed pregnancy
    • 3.2.1.3 High unmet contraceptive needs in developing economies
    • 3.2.1.4 Growing prevalence of sexually transmitted diseases (STD)
    • 3.2.1.5 Government initiatives raising awareness about male sterilization
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Availability of alternative methods
    • 3.2.2.2 Risk associated with vasectomy surgeries
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Innovation and sustainability
  • 3.5.1 Technological innovations in non-hormonal contraceptives
  • 3.5.2 Sustainability initiatives and eco-friendly products
• 3.6 Reimbursement scenario
• 3.7 Gap analysis
• 3.8 Pricing analysis
• 3.9 Condoms and IUDs - global and regional volume analysis, 2024
• 3.10 Distribution outlook for devices
• 3.11 Consumer behavior analysis
• 3.12 Porter's analysis
• 3.13 PESTEL analysis
• 3.14 Value chain analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Devices
  • 5.2.1 Condoms
    • 5.2.1.1 Male
    • 5.2.1.2 Female
  • 5.2.2 Intra-uterine devices
  • 5.2.3 Vaginal rings
  • 5.2.4 Subdermal implants
  • 5.2.5 Other devices
• 5.3 Sterilization
  • 5.3.1 Vasectomy
    • 5.3.1.1 No-scalpel vasectomy
    • 5.3.1.2 Conventional vasectomy
    • 5.3.1.3 Minimally invasive vasectomy
  • 5.3.2 Tubal ligation
    • 5.3.2.1 Laparoscopic tubal ligation
    • 5.3.2.2 Hysteroscopic tubal ligation
    • 5.3.2.3 Mini-Laparotomy
    • 5.3.2.4 Other procedures
• 5.4 Other product types

Chapter 6 Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Male
• 6.3 Female

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 15-44 years
• 7.3 Above 44 years

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 abbVie
• 9.2 Bayer
• 9.3 Church & Dwight Co.
• 9.4 CooperCompanies
• 9.5 CUPID
• 9.6 FUJI LATEX
• 9.7 HLL Lifecare
• 9.8 Mankind
• 9.9 MAYER
• 9.10 VIATRIS
• 9.11 Okamoto
• 9.12 PREGNA INTERNATIONAL
• 9.13 reckitt
• 9.14 SMB
• 9.15 veru